TET2 and cyclic hematopoiesis: It is still unclear if the beneficial effects of Tet2-mediated CH on stroke outcomes would differ in individuals with cardiovascular risk factors, particularly atherosclerosis and hypertension, which are aggravated by hematopoietic Tet2 mutations (Fuster et al., 2017; Polizio et al., 2024).